HVTN 084

Principal Investigator(s):Esper Kallas, MD, PhD
Objective:To test whether a vaccine that targets Gag and another peptide called Env is better than a vaccine without Env at causing an immune response to Gag. *Trial is in follow-up*
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionRecombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
Mode of DeliveryIntramuscular
DescriptionParticipants will receive one intramuscular injection of rAd5 gag/pol.
Mode of DeliveryIntramuscular
ARMsPlacebo Comparator
Official Code: NCT01159990
Trial Sponsors: NIAID
Start Date
End Date
January 31, 2011
August 31, 2012
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women